FREMONT, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(Nasdaq: ABGX) today announced that the company will present at BIO CEO &
Investor Conference on Thursday, February 24, 2005 at 12:00 p.m. PT, 3:00 p.m.
ET. The presentation will be webcast live and may be accessed by visiting the
Abgenix website at http://www.abgenix.com. A replay of the webcast will also be
available on the company's website until Thursday, March 10, 2005.
Bill Ringo, president and chief executive officer of Abgenix, will provide
an update on the company's antibody drug development activities.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and state-of-the-
art manufacturing capabilities that enable the rapid generation, selection and
production of high affinity, fully human antibody product candidates to a
variety of disease targets. Abgenix leverages its leadership position in human
antibody technology to build a diversified product portfolio through its own
development efforts and through the establishment of collaborations with
multiple pharmaceutical and biotechnology companies. For more information on
Abgenix, visit the company's website at http://www.abgenix.com.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
Ami Knoefler, Senior Director, Corporate
Communications and Investor Relations, of Abgenix, Inc.,
+1-510-284-6350 or +1-510-284-6605
|
